11 results
8-K
EX-99.2
LHDXQ
Lucira Health, Inc.
12 Nov 21
Lucira Health Announces Third Quarter 2021 Financial Results and Provides Business Update
6:04am
services to facilitate commercial activities and public company compliance.
R&D expenses were $14.8 million in the third quarter of 2021, compared
8-K
EX-99.1
LHDXQ
Lucira Health, Inc.
12 Jun 23
Other Events
4:02pm
on March 24, 2023 [D.I. 179].
R&D Claims Motion. On March 2, 2023, the Debtor Filed the Debtor’s Motion for Entry of an Order (I) Authorizing the Debtor … Course of Business; and (III) Granting Related Relief [D.I. 62] (the “R&D Claims Motion”), seeking an order (i) authorizing, but not directing
10-K
2020 FY
LHDXQ
Lucira Health, Inc.
31 Mar 21
Annual report
5:16pm
relationships.
Research and Development
As of December 31, 2020, our research and development, or R&D, team consisted of 20 people conducting research … and product development activities. Our R&D team has been working on developing our platform over the last seven years and have optimized the device
S-1/A
LHDXQ
Lucira Health, Inc.
1 Feb 21
IPO registration (amended)
7:58am
research and development, or R&D, team consisted of 20 people conducting research and product development activities. Our R&D team has been working … clinical and pre-clinical studies. Our R&D team is focused on three core areas: creation of new products for existing markets and unmet needs
DRS/A
ggrcid j3kn
23 Dec 20
Draft registration statement (amended)
12:00am
S-1
gs0af
15 Jan 21
IPO registration
4:53pm
424B4
euq14mg8z68tiyff 9l
8 Feb 21
Prospectus supplement with pricing info
11:06am
DRS
5en493gxc4j 2k
23 Nov 20
Draft registration statement
12:00am
- Prev
- 1
- Next